Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Regeneron initiates phase II study of REGN-2477 for fibrodysplasia ossificans progressiva

Nov. 24, 2017

Shionogi & Co. patents new AMPK activators for diabetes

Nov. 23, 2017

Teijin's TEI-A reduces uric acid levels in preclinical tests

Nov. 23, 2017

Adocia reports phase I results for BioChaperone Glucagon

Nov. 21, 2017

FDA grants breakthrough therapy designation to patisiran

Nov. 21, 2017

Alnylam Pharmaceuticals begins rolling NDA submission for patisiran

Nov. 17, 2017

FDA issues alert regarding Takeda's febuxostat for gout

Nov. 17, 2017

Gout candidate URC-102 shows promise in phase II trials

Nov. 16, 2017

Sangamo treats first patient with in vivo genome editing therapy SB-913 for MPS II

Nov. 16, 2017

FDA approves Mepsevii for mucopolysaccharidosis type VII

Nov. 16, 2017

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...